-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Christian Rolfo, MD, PhD, MBA
Posted: August 2018 As of April 2018, Christian Rolfo, MD, PhD, MBA, is the director of the Thoracic Medical Oncology and the Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) and professor in medicine at the University of Marlyland School of Medicine. Previously, Dr. Rolfo was director…
-
Leena Gandhi, MD, PhD
Posted: August 2018 Leena Gandhi, MD, PhD, has become head of oncology for Eli Lilly and Company, where she will direct research of the company’s immuno-oncology products. Previously, she was director of thoracic medical oncology at New York University (NYU) Langone Medical Center LLC. Prior to joining NYU Langone and the Perlmutter Cancer Center, Dr.…
-
Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care
By Kara Nyberg, PhD Posted: August 2018 Treatment advances for metastatic squamous cell carcinoma have long lagged behind those for other NSCLC subtypes, forcing patients with this difficult-to-treat disease to settle with platinum-based chemotherapy as the best treatment option. But the tide now appears to be turning. As presented at the American Society of Clinical…
-
Navneet Singh, MD
Posted: August 2018 Navneet Singh, MD, the IASLC’s Regent from India, has been appointed chair of the IDEA working group for the American Society of Clinical Oncology. Dr. Singh will serve a 2-year term. Dr. Singh is also on the IASLC’s Staging Committee, and he leads the multidisciplinary thoracic oncology group at PGIMER, where he…
-
Austria’s Reversal of Smoking Ban in World Spotlight
Posted: August 2018 Tobacco harms the health, the treasury, and the collective spirit of Austria. In May 2018, a smoking ban was scheduled to begin in all bars and restaurants in Austria; however, the ban was recently overturned by lawmakers from a new ruling coalition in the government, the People’s Party and the Freedom Party. In…
-
Julie R. Brahmer, MD, MSc
Posted: August 2018 Julie R. Brahmer, MD, MSc, director of thoracic oncology program and professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, has been recognized as 2018 Oncologist of The Year by Continental Who’s Who, a business publisher. Dr. Brahmer directs the Kimmel Cancer Center on the Johns Hopkins Bayview…
-
Motivated, Engaged, and Organized: The New Molecular Cohorts of Lung Cancer
By D.R. Camidge Posted: June 2018 Just as physicians and scientists no longer treat lung cancer as a single disease because of molecular distinctions, patient advocacy groups also are becoming organized along molecular lines. In 2015, Janet Freeman-Daily, Lisa Goldman, and Tori Tomalia—all ROS1– positive NSCLC survivors—co-founded a private Facebook group, ”ROS1 Positive (ROS1+) Cancer.”…
-
HLA LOH As an Immune Evasive Mechanism in TRACERx NSCLC
By Rachel Rosenthal, PhD, MSc, andCharles Swanton, FRCP, BSc, PhD Posted: June 2018 An evolving tumor and the immune system continuously adapt to each other. As a tumor develops increasing numbers of somatic alterations and disregulated genes, it must also find ways to avoid immune detection and elimination by activated immune cells.1 One route to…
-
Israel's Parliament Hosts IASLC CEO Dr. Fred R. Hirsch
By Shani Shilo, DMD, PhD, andNir Peled, MD, PhD, FCCP Posted: June 2018 On March 6, 2018, the Israeli parliament, the Knesset, held a Science and Technology Committee meeting devoted to lung cancer, new technologies, and their effects on the future of care. The meeting was an initiative of the Israel Lung Cancer Foundation and…
-
NCCN Guidelines Updated for 2018: Keeping Pace with Data
By Gregory J. Riely, MD Posted: June 2018 The changes seen in the 2018 update of the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of patients with NSCLC reflect the rapid and significant progress we have observed in the treatment of lung cancer over the past 12…
View ILCN Archives
Provider Resources
Popular Articles